{
    "clinical_study": {
        "@rank": "8337", 
        "arm_group": [
            {
                "arm_group_label": "IV Acetaminophen", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given."
            }, 
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized controlled trial will evaluate the effects of perioperative intravenous (IV)\n      acetaminophen on postoperative narcotic consumption and pain scores in subjects undergoing\n      vaginal reconstructive surgery. One hundred subjects will be randomly assigned to receive\n      either IV acetaminophen or IV placebo. Those in the IV acetaminophen group will receive\n      1000mg IV every 6 hours for 24 hours beginning prior to anesthesia induction. The control\n      group will receive placebo saline infusions at the same time intervals. All subjects will\n      receive as needed (prn) IV narcotic for additional pain relief. Visual analog scales (VAS)\n      regarding pain will be evaluated at 18 and 24 hours postoperative and immediately prior to\n      discharge. We will also collect total IV narcotic consumption.  We hypothesize that subjects\n      receiving IV acetaminophen will have lower VAS scores and decreased total narcotic\n      consumption in comparison to the control group."
        }, 
        "brief_title": "RCT of IV Acetaminophen for Post Operative Vaginal Reconstruction Pain", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Post Operative Pain", 
        "condition_browse": {
            "mesh_term": "Pain, Postoperative"
        }, 
        "detailed_description": {
            "textblock": "see brief summary"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women between the ages of 18 and 70 years\n\n          -  Patients of the Division of Urogynecology at Good Samaritan and Bethesda North\n             Hospitals in Cincinnati, Ohio\n\n          -  Scheduled to undergo major vaginal reconstruction\n\n          -  Must undergo total vaginal hysterectomy, anterior repair, posterior repair,\n             enterocele repair, and intraperitoneal vault suspension. The addition of suburethral\n             sling is not a cause for exclusion.\n\n        Exclusion Criteria:\n\n          -  Allergy to acetaminophen\n\n          -  Liver disease (chronic or active)\n\n          -  Chronic alcohol use (>1 drink/day)\n\n          -  Bleeding diathesis\n\n          -  Renal disease\n\n          -  Opiate dependent or daily use\n\n          -  History of chronic pain\n\n          -  Mental or cognitive disorder preventing patient to accurately verbalize pain levels\n\n          -  Undergoing abdominal or laparoscopic procedures at the time of surgery\n\n          -  Allergy to hydromorphone\n\n          -  Surgery is not performed under general anesthesia"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02043704", 
            "org_study_id": "13072"
        }, 
        "intervention": {
            "arm_group_label": "IV Acetaminophen", 
            "description": "Details covered in arm description.", 
            "intervention_name": "IV Acetaminophen", 
            "intervention_type": "Drug", 
            "other_name": "Ofirmev"
        }, 
        "intervention_browse": {
            "mesh_term": "Acetaminophen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "IV Acetaminophen", 
            "Vaginal Reconstruction", 
            "Pain, Postoperative"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "location": {
            "contact": {
                "email": "michaela_eschenbacher@trihealth.com", 
                "last_name": "Michaela Eschenbacher, MPH", 
                "phone": "513-862-2341"
            }, 
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45220"
                }, 
                "name": "TriHealth - Good Samaritan and Bethesda North Hospitals"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Intravenous Acetaminophen on Post-operative Pain and Narcotic Consumption in Vaginal Reconstructive Surgery Patients: A Randomized Controlled Trial", 
        "other_outcome": [
            {
                "description": "Length of time from the end of surgery to the time of ambulation.", 
                "measure": "Time to ambulation", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Length of time from the end of surgery to the time of first flatus or bowel movement.", 
                "measure": "Time to first flatus/bowel movement", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "overall_contact": {
            "email": "catrina_crisp@trihealth.com", 
            "last_name": "Catrina Crisp, MD, MSc", 
            "phone": "513-819-0798"
        }, 
        "overall_contact_backup": {
            "email": "madiha_khan@trihealth.com", 
            "last_name": "Madiha Khan, MD", 
            "phone": "513-819-0005"
        }, 
        "overall_official": {
            "affiliation": "TriHealth Inc.", 
            "last_name": "Catrina Crisp, MD, MSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Post operative pain will be assessed 18 and 24 hours after surgery and immediately prior to discharge. Pain will be self reported by patients using a 10cm visual analog scale (VAS). At each time point a pain score will be collected for pain at rest and pain with ambulation or an action symbolizing ambulation (i.e. coughing).", 
                "measure": "Post Operative Pain", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Hydromorphone will be administered for breakthrough pain. The total amount consumed in the first 24 hours post surgery will be recorded.", 
                "measure": "Total amount of narcotic consumption in the first 24 hours post surgery", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02043704"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The incidence of known narcotic associated side effects will be recorded, including: nausea, emesis, itching, headache, insomnia, rash/hives, shortness of breath, respiratory depression, and urinary retention.", 
                "measure": "Narcotic associated side effects", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "The time from the end of surgery to the time any IV narcotic is given.", 
                "measure": "Time to first rescue narcotic", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "TriHealth Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TriHealth Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}